-+ 0.00%
-+ 0.00%
-+ 0.00%

EU Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer

PUBT·11/16/2026 18:00:42
Listen to the news
EU Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer
  • European Commission approves Revolution Medicines’ Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma.
  • The once-daily oral monotherapy is indicated for adults who have received at least one prior systemic therapy, regardless of RAS mutation status.
  • Patient access depends on country-specific pricing and reimbursement processes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161300PRIMZONEFULLFEED9878650) on November 16, 2026, and is solely responsible for the information contained therein.